Loading...
NPI 1720737786 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vcare Testing Centre Corp. is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 1 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Vcare Testing Centre Corp. |
| Address | 7545 W Irving Park Rd |
| City | Chicago |
| State | IL |
| ZIP | 60634 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 18, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $13.1M |
| Medicaid | $43.4K |
VCARE TESTING CENTRE CORP. is a clinical medical laboratory based in CHICAGO, IL with an NPI enumerated 2022-03-18 (~4 years ago). Its billing profile is overwhelmingly Medicare-weighted by dollars, with Total Medicare revenue reported as $13.1M versus Total Medicaid revenue of $43.4K, indicating Medicare is the primary revenue source for the business.
Medicare revenue is completely dominated by a single code: K1034 (Provision of covid-19 test, nonprescription self-administered and self-collected use), which accounts for $13.1M and 1.1M claims at $12 avg paid/claim and represents 100.0% of this provider's total Medicare revenue. That single-code concentration implies the provider’s Medicare activity is essentially focused on large-scale provisioning of nonprescription/self-administered COVID-19 tests rather than a broad menu of lab services.
K1034 is an exceptional national outlier for this provider: it ranks #39 of 30143 providers nationally and is described as an "extreme outlier, far above typical national volume for this code". This ranking indicates the provider is a major national-volume participant for K1034 specifically, rather than being a typical clinical lab in Medicare testing volumes.
On the Medicaid side, the top three Medicaid codes (87811, G2023, 0240U) together account for 85.9% of the provider's total Medicaid revenue, signaling a concentrated but slightly more diverse Medicaid mix than Medicare. The largest Medicaid contributors are 87811 ($18.8K, 458 claims, $41 avg paid/claim; 43.2% of Medicaid revenue), G2023 ($12.4K, 540 claims, $23 avg paid/claim; 28.6%), and 0240U ($6.1K, 52 claims, $118 avg paid/claim; 14.1%), which reflect a combination of immunoassay lab analysis and specimen-collection services plus a smaller-volume proprietary/other test code.
Competitive standing in-state is mixed: 87811 ranks #189 of 548 providers (66th percentile) and G2023 ranks #199 of 396 providers (50th percentile), both characterized as typical, unremarkable volumes for those codes. By contrast, the Medicaid appearance of K1034 (6.1K claims, $1 avg paid/claim, $6.1K revenue) ranks #3 of 59 providers in-state (97th percentile) and is labeled "notably above typical state volume," indicating the provider also distributes high volumes of the OTC COVID-19 test to Medicaid beneficiaries even though those claims generate relatively low per-claim revenue.
The dual-payer pattern shows high operational specialization: Medicare revenue is essentially single-code dependent (precomputed top 3 codes = 100.0%), while Medicaid receipts are concentrated but split across laboratory analysis and specimen collection codes (precomputed top 3 codes = 85.9%). This asymmetric payer mix and code concentration signal business risk if reimbursement or demand for K1034 changes, but also reflect a clear service-line focus on COVID-19 testing and test provisioning.
Despite being enumerated only since 2022-03-18 (~4 years ago), the provider scaled to substantial Medicare volume for K1034 very quickly, which suggests a rapid operational buildout or a business model centered on distributing nonprescription/self-administered COVID-19 tests. Analysts should interpret the fast growth to a single high-volume code as an operational footprint that is narrow in scope but large in transactional volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,092,630 | $10 | $13.1M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 14 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 460 | $40 | $18.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 540 | $20 | $12.4K |
| 0240U | N/A | 50 | $120 | $6.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 6,110 | $1 | $6.1K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 0240U | N/A | 18 | 20 | 240 | $120 | $403.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 199 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 189 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Vcare Testing Centre Corp., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Primecare Community Health Inc. | IL | Federally Qualified Health Center (FQHC) | $0 | $11.7M |
| Vickie Rezai | IL | Anatomic Pathology & Clinical Pathology Physician | $0 | $5.9M |
| Natalia Surowaniec | IL | Family Nurse Practitioner | $2.1M | $0 |
| Godwin D'souza | IL | Internal Medicine Physician | $589.2K | $598.3K |
| Shirish Shah | IL | Cardiovascular Disease Physician | $325.8K | $595.7K |
| Malik Zayed | IL | Podiatrist | $428.7K | $360.9K |
| Premesh Malapati | IL | Internal Medicine Physician | $266.8K | $391.5K |
| Steven Eidt | IL | Ophthalmology Physician | $249.7K | $402.7K |
| Belmont/harlem Surgery Center, LLC | IL | Ambulatory Surgical Clinic/Center | $642.4K | $10 |
| Kathleen Scarpulla | IL | Ophthalmology Physician | $385.8K | $77.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.